Drug Patent Watch

OCTOBER 16, 2024

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems.

Biosimilars 115

Biosimilars Drug Development Drugs Pharmaceuticals 115

Drugs.com

FEBRUARY 19, 2025

Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. WEDNESDAY, Feb. 19, 2025 -- The U.S. Merilog is a rapid-acting human.

Biosimilars 147

Biosimilars FDA Approval FDA Drugs 147

Drug Patent Watch

JULY 9, 2024

The introduction of biosimilars has significantly altered the landscape of biologic drug distribution models. Biosimilars, which are highly similar to […] Source

Biosimilars 104

Biosimilars Drugs 104

Drugs.com

FEBRUARY 19, 2025

Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.Merilog is a rapid-acting human. WEDNESDAY, Feb. 19, 2025 -- The U.S.

Biosimilars 130

Biosimilars FDA Approval FDA Drugs 130

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.

Biosimilars 130

Biosimilars Marketing Drugs 130

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. Net prices in therapeutic classes with biosimilar competition have declined by 60% or more over the past few years. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. drug distribution.

Biosimilars 97

Biosimilars Drugs Pharmaceuticals Production 97

Drug Patent Watch

DECEMBER 10, 2024

Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.

Biosimilars 97

Biosimilars Drugs Production Clinical Trials 97

Drug Patent Watch

DECEMBER 8, 2024

However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies. In this article, we will delve into the strategies and considerations for handling drug patent… Source

Biosimilars 98

Biosimilars Pharmaceutical Companies Drugs Pharmaceuticals 98

BioPharma Drive: Drug Pricing

JUNE 28, 2024

European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan.

Biosimilars 167

Biosimilars Regulations Drugs Disease 167

DrugBank

SEPTEMBER 26, 2024

Biosimilars  Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

Biosimilars 98

Biosimilars Clinical Trials Production FDA 98

BioPharma Drive: Drug Pricing

APRIL 19, 2024

The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

Biosimilars 196

Biosimilars Marketing Drugs 196

BioPharma Drive: Drug Pricing

APRIL 26, 2024

Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.

Biosimilars 184

Biosimilars Drugs 184

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Licensing 96

Licensing Licensing Drugs Biosimilars 96

BioPharma Drive: Drug Pricing

JULY 18, 2024

The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.

Biosimilars 190

Biosimilars Drugs 190

BioPharma Drive: Drug Pricing

JULY 26, 2024

Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs. Glycomimetics and Cue Biopharma both revealed layoffs.

Biosimilars 167

Biosimilars FDA Drugs 167

Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. d/b/a Drug Channels Institute. Will payers let Humira go?

Biosimilars 98

Biosimilars Pharmacy Marketing Drugs 98

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Marketing Drugs Production 98

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Biosimilars 98

Biosimilars Pharmacy Marketing Pharmaceuticals 98

Drug Patent Watch

MARCH 31, 2024

A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,… Source

Biosimilars 105

Biosimilars Drugs Research 105

Drug Patent Watch

AUGUST 15, 2023

A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs.

Biosimilars 98

Biosimilars Therapies Treatment Disease 98

Drug Channels

JANUARY 10, 2023

For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

BioPharma Drive: Drug Pricing

OCTOBER 23, 2024

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as litigation continues.

Biosimilars 157

Biosimilars Drugs 157

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. d/b/a Drug Channels Institute. This Feed is for personal non-commercial use only.

Biosimilars 98

Biosimilars Drugs Production Marketing 98

Drug Channels

MARCH 28, 2023

For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

BioPharma Drive: Drug Pricing

APRIL 5, 2024

The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

Biosimilars 167

Biosimilars Pharmaceutical Companies Pharmaceuticals Disease 167

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Marketing Drugs 98

Drug Channels

JANUARY 9, 2024

For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. This year, Humira and its 13 biosimilars will provide the most intriguing formulary drama. All rights reserved.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

OCTOBER 14, 2022

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution.

Biosimilars 98

Biosimilars Pharma Companies Marketing Research 98

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. d/b/a Drug Channels Institute. P.S. Join my nearly 30,000 (!) to 1:30 p.m.

Biosimilars 98

Biosimilars Pharmacy Drugs Marketing 98

Drug Channels

SEPTEMBER 13, 2022

Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 97

Biosimilars Pharmacy Hospitals Marketing 97

BioPharma Drive: Drug Pricing

JUNE 29, 2023

The latest regulatory setback, tied to continuing manufacturing issues, ensures Alvotech and partner Teva won’t be able to launch their drug alongside a wave of emerging Humira copycats.

Biosimilars 157

Biosimilars FDA Drugs 157

Drug Channels

OCTOBER 31, 2023

It's time for a super-sized Halloween roundup of wicked Drug Channels ’ tales. CVS Health frightens all but one Humira biosimilar maker away from its formulary. The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Mark Cuban Cost Plus Drug Company conjures a partnership with Alto Pharmacy.

Biosimilars 98

Biosimilars Pharmacy Drugs 98

Drug Channels

DECEMBER 12, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. d/b/a Drug Channels Institute. 117-169).

Biosimilars 98

Biosimilars Pharmacy Hospitals Marketing 98

Drug Channels

DECEMBER 11, 2023

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Pharmacy Production Marketing 75

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars 75

Biosimilars Pharmacy Drugs Marketing 75

BioPharma Drive: Drug Pricing

JUNE 16, 2023

Best known for its work in biosimilars, Coherus will acquire two drugs in human testing for various solid tumors through a roughly $65 million buyout of Surface Oncology.

Biosimilars 157

Biosimilars Drugs 157

Drug Channels

AUGUST 23, 2022

Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline: Howard Dean attacks patient-unfriendly cost shifting Cancer patients’ views of copay assistance My $0.02 d/b/a Drug Channels Institute.

Biosimilars 75

Biosimilars Specialty Pharmacies Pharmacy Drugs 75